|
1
|
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
|
N Engl J Med
|
2011
|
45.46
|
|
2
|
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
|
N Engl J Med
|
2011
|
26.90
|
|
3
|
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
|
Lancet
|
2008
|
3.62
|
|
4
|
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.
|
Genes Dev
|
2006
|
2.87
|
|
5
|
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria.
|
J Clin Oncol
|
2011
|
2.62
|
|
6
|
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
|
J Clin Oncol
|
2002
|
2.57
|
|
7
|
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
|
J Clin Oncol
|
2009
|
2.50
|
|
8
|
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
|
Lancet Neurol
|
2009
|
2.48
|
|
9
|
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
|
J Clin Oncol
|
2012
|
2.42
|
|
10
|
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
|
Lancet Oncol
|
2012
|
2.03
|
|
11
|
The role of BRAF V600 mutation in melanoma.
|
J Transl Med
|
2012
|
2.00
|
|
12
|
Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases.
|
Crit Rev Oncol Hematol
|
2007
|
1.75
|
|
13
|
Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up.
|
Blood
|
2010
|
1.74
|
|
14
|
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma.
|
Eur J Nucl Med Mol Imaging
|
2009
|
1.68
|
|
15
|
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
|
J Clin Oncol
|
2013
|
1.67
|
|
16
|
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
|
Lancet
|
2005
|
1.60
|
|
17
|
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.
|
J Transl Med
|
2014
|
1.59
|
|
18
|
The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1,313 patients with cutaneous melanoma: an Italian Multicentric Study (SOLISM-IMI).
|
J Nucl Med
|
2006
|
1.53
|
|
19
|
Clinical genetic testing for familial melanoma in Italy: a cooperative study.
|
J Am Acad Dermatol
|
2009
|
1.45
|
|
20
|
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
|
Eur J Cancer
|
2011
|
1.28
|
|
21
|
Vitamin D and skin cancer: a meta-analysis.
|
Eur J Cancer
|
2008
|
1.22
|
|
22
|
Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer.
|
Cancer Immunol Immunother
|
2003
|
1.20
|
|
23
|
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.
|
Cancer Immunol Immunother
|
2011
|
1.19
|
|
24
|
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
|
Cancer Invest
|
2014
|
1.06
|
|
25
|
Primary and recurrent retroperitoneal soft tissue sarcoma: prognostic factors affecting survival.
|
J Surg Oncol
|
2006
|
1.03
|
|
26
|
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.
|
Cancer
|
2008
|
1.03
|
|
27
|
Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
|
J Clin Oncol
|
2010
|
1.00
|
|
28
|
Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma.
|
Clin Cancer Res
|
2007
|
0.99
|
|
29
|
Anti-CTLA-4 antibody adjuvant therapy in melanoma.
|
Semin Oncol
|
2010
|
0.97
|
|
30
|
Desmoid tumors of the anterior abdominal wall: results from a monocentric surgical experience and review of the literature.
|
Ann Surg Oncol
|
2009
|
0.96
|
|
31
|
Genome-wide activity of unliganded estrogen receptor-α in breast cancer cells.
|
Proc Natl Acad Sci U S A
|
2014
|
0.95
|
|
32
|
Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
|
J Clin Oncol
|
2010
|
0.93
|
|
33
|
Recurrence and prognostic factors in patients with aggressive fibromatosis. The role of radical surgery and its limitations.
|
World J Surg Oncol
|
2012
|
0.93
|
|
34
|
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.
|
J Clin Oncol
|
2013
|
0.92
|
|
35
|
Sentinel node biopsy in thin and thick melanoma.
|
Ann Surg Oncol
|
2013
|
0.92
|
|
36
|
Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).
|
Cancer Chemother Pharmacol
|
2009
|
0.92
|
|
37
|
Treatment of metastatic melanoma with electrochemotherapy.
|
J Surg Oncol
|
2014
|
0.91
|
|
38
|
The cost of unresectable stage III or stage IV melanoma in Italy.
|
J Exp Clin Cancer Res
|
2012
|
0.91
|
|
39
|
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme.
|
J Exp Clin Cancer Res
|
2014
|
0.89
|
|
40
|
Hematopoietic stem cell transplantation for autoimmune diseases: what have we learned?
|
J Autoimmun
|
2008
|
0.89
|
|
41
|
Heat shock proteins and their use as anticancer vaccines.
|
Clin Cancer Res
|
2004
|
0.87
|
|
42
|
Pediatric melanoma: analysis of an international registry.
|
Cancer
|
2013
|
0.86
|
|
43
|
Diagnostic and therapeutic imaging for cancer: therapeutic considerations and future directions.
|
J Surg Oncol
|
2011
|
0.86
|
|
44
|
Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.
|
Recent Pat Anticancer Drug Discov
|
2008
|
0.85
|
|
45
|
Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents.
|
Expert Opin Biol Ther
|
2014
|
0.85
|
|
46
|
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.
|
J Exp Clin Cancer Res
|
2013
|
0.84
|
|
47
|
Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma.
|
Dermatology
|
2013
|
0.83
|
|
48
|
EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma.
|
Eur J Nucl Med Mol Imaging
|
2015
|
0.83
|
|
49
|
Computer-aided diagnosis of melanocytic lesions.
|
Anticancer Res
|
2005
|
0.83
|
|
50
|
Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?
|
Clin Exp Metastasis
|
2012
|
0.82
|
|
51
|
Surgical management of suspicious melanocytic lesions in Italy.
|
Dermatology
|
2013
|
0.82
|
|
52
|
Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients?
|
Eur Radiol
|
2013
|
0.82
|
|
53
|
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
|
Eur J Cancer
|
2009
|
0.80
|
|
54
|
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.
|
J Transl Med
|
2014
|
0.80
|
|
55
|
Modification of lymphoscintigraphic sentinel node identification before and after excisional biopsy of primary cutaneous melanoma.
|
Melanoma Res
|
2008
|
0.79
|
|
56
|
Subcutaneous immunoglobulins: product characteristics and their role in primary immunodeficiency disease.
|
Int Rev Immunol
|
2012
|
0.79
|
|
57
|
Clinical and dermoscopic criteria related to melanoma sentinel lymph node positivity.
|
Anticancer Res
|
2007
|
0.79
|
|
58
|
HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.
|
Expert Rev Vaccines
|
2009
|
0.78
|
|
59
|
The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease.
|
Expert Opin Biol Ther
|
2011
|
0.78
|
|
60
|
Sunny holidays before and after melanoma diagnosis are respectively associated with lower Breslow thickness and lower relapse rates in Italy.
|
PLoS One
|
2013
|
0.77
|
|
61
|
Oncophage: step to the future for vaccine therapy in melanoma.
|
Expert Opin Biol Ther
|
2008
|
0.77
|
|
62
|
Pulsed dose-rate perioperative interstitial brachytherapy for soft tissue sarcomas of the extremities and skeletal muscles of the trunk.
|
Ann Surg Oncol
|
2005
|
0.77
|
|
63
|
What is new in melanoma research? Vaccines, Basic and Translational Research in 2003: report of a workshop at the Third Research Meeting on Melanoma, Milan, Italy, May 2003.
|
Melanoma Res
|
2004
|
0.77
|
|
64
|
Autologous hematopoietic stem cell transplantation for systemic sclerosis.
|
Curr Stem Cell Res Ther
|
2011
|
0.77
|
|
65
|
Cutaneous melanoma: digital dermoscopy-essential tool for positive diagnosis.
|
J Cell Mol Med
|
2006
|
0.76
|
|
66
|
Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
|
Melanoma Res
|
2015
|
0.76
|
|
67
|
Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative Group.
|
Int J Oncol
|
2003
|
0.76
|
|
68
|
Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations.
|
Melanoma Res
|
2008
|
0.75
|
|
69
|
Combined approach for the biomechanical characterization of skin lesions.
|
Conf Proc IEEE Eng Med Biol Soc
|
2015
|
0.75
|
|
70
|
What is new in melanoma research: genetics and epidemiology of melanoma in 2003? Review of a workshop held in Milan in May 2003.
|
Melanoma Res
|
2004
|
0.75
|
|
71
|
Update: current management issues in malignant melanoma.
|
Melanoma Res
|
2005
|
0.75
|
|
72
|
Melanoma Task Force (META) Project in Italy: methodology.
|
Dermatology
|
2013
|
0.75
|
|
73
|
Dermatoscopic and histopathological diagnosis of primary and metastatic melanoma: report of a workshop at the Third Research Meeting on Melanoma, Milan, Italy, May 2003.
|
Melanoma Res
|
2004
|
0.75
|
|
74
|
Management of small and intermediate congenital nevi: a nationwide survey in Italy.
|
Dermatology
|
2013
|
0.75
|
|
75
|
Pelvic sentinel lymph node biopsy in melanoma patients: is it worthwhile?
|
Melanoma Res
|
2010
|
0.75
|
|
76
|
Melanoma - what is new in sentinel node biopsy and locoregional treatments in 2003? Report of a workshop at the Third Research Meeting on Melanoma, Milan, Italy, May 2003.
|
Melanoma Res
|
2004
|
0.75
|
|
77
|
Impact of mole mapping in the Italian health system.
|
Dermatology
|
2013
|
0.75
|
|
78
|
Diagnostic services for melanoma in Italy.
|
Dermatology
|
2013
|
0.75
|
|
79
|
Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.
|
Curr Top Med Chem
|
2012
|
0.75
|
|
80
|
Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).
|
Cancer Immunol Immunother
|
2013
|
0.75
|
|
81
|
[The method of the sentinel lymph node].
|
Chir Ital
|
2002
|
0.75
|
|
82
|
Unknown Primary Melanoma: Worldwide Survey on Clinical Management.
|
Dermatology
|
2017
|
0.75
|